Retatrutide adds two Phase 3 wins with A1C and weight-loss results

The strongest public story from the last few days is not a new brand fight or another access dispute. It is the next retatrutide readout. Drug Topics reports that Lilly's once-weekly triple agonist has now produced positive topline results in TRIUMPH-2 and TRIUMPH-3, two late-stage trials in adults with obesity and major metabolic or cardiovascular comorbidity. That moves the program from promise toward a real regulatory package.

The numbers are the reason this deserves the lead slot. In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes lost up to an average of 20.8%, or 49.6 pounds, over 80 weeks, while A1C fell by as much as 1.6 percentage points. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to an average of 22.6%, or 55.8 pounds, with additional movement in markers such as triglycerides, non-HDL cholesterol, blood pressure, waist circumference, and high-sensitivity C-reactive protein.

The program now has five positive Phase 3 trials, which is the real editorial threshold. One result can be interesting; a multi-trial package starts to define what pharmacists, clinicians, payers, and patients may need to understand if the product reaches review. The reporting also keeps the cardiovascular question appropriately measured: the available composite-event analyses are not enough to claim an outcomes benefit, but they are part of the evidence regulators and clinicians will want to examine.

Lilly plans to submit a biologics license application for obesity in the first quarter of 2027. That is a planned filing, not FDA approval, and the full trial publications and meeting presentations still matter. This is not medical advice or treatment guidance. For readers, the point is not to chase an investigational medicine. It is to understand why retatrutide is becoming one of the most important next-generation peptide programs to watch.

Retatrutide is investigational and is not FDA-approved. This is educational news context, not medical advice or treatment guidance.

Read the full story at Drug Topics ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.